New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination
We report a 56-year-old male who developed cutaneous lichen planus (LP) following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination. Multiple topical and systemic therapies were tried with limited success; however, partial improvement was observed with narrow-band UVB (NB-UVB) phototherapy. This r...
        Saved in:
      
    
          | Main Authors: | Amira Muftah, Stephen Lee, Mariam Abbas | 
|---|---|
| Format: | Article | 
| Language: | English | 
| Published: | SAGE Publishing
    
        2024-12-01 | 
| Series: | SAGE Open Medical Case Reports | 
| Online Access: | https://doi.org/10.1177/2050313X241307109 | 
| Tags: | Add Tag 
      No Tags, Be the first to tag this record!
   | 
Similar Items
- 
                
                    Oxford-AstraZeneca Coronavirus Disease-2019 Vaccine-Induced Immune Thrombocytopenia on Day Two        
                          
 by: Azhar Kareem Razzaq, et al.
 Published: (2021-01-01)
- 
                
                    Busting the Breast Cancer with AstraZeneca’s Gefitinib        
                          
 by: S. Chemmalar, et al.
 Published: (2023-01-01)
- 
                
                    Case report of secondary T-cell deficiency following the AstraZeneca COVID-19 vaccine        
                          
 by: Amin Esmailian, BSC (Hons), MD, et al.
 Published: (2024-11-01)
- 
                
                    New Tendencies in the Development of the EU Competition Law – the AstraZeneca case        
                          
 by: K. V. Entin
 Published: (2011-10-01)
- 
                
                    Extensive Longitudinal Transverse Myelitis Temporally Related to the Use of AZD1222, AstraZeneca COVID-19 Vaccine: Cerebrospinal Fluid Analysis and Recent Data Review        
                          
 by: Paulo Diniz da Gama, et al.
 Published: (2022-01-01)
 
       